A cell therapy reckoning
Listen now
Description
The Fierce Biotech team published a four-part series this week exploring cell therapy, a modality that has faced clinical challenges, manufacturing constraints and multiple practice-changing events.   In today’s episode, Fierce’s Annalee Armstrong and Gabrielle Masson discuss the series of special reports and key insights from their interviews with multiple experts.   To learn more about the topics in this episode:  Cell therapy reckoning: How a 'remarkable resolution of lupus' carried CAR-T from cancer to immunology Cell therapy reckoning: Pivot to autoimmune leaves unmet need in oncology Biotech faces a reckoning: 'We've lost our luster in cell therapies' Fulfilling the promise of cell & gene therapies through manufacturing (Part I) From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) Automation, decentralization and the future of CAR-Ts: Advancements in cell & gene therapy manufacturing (Part III)   See omnystudio.com/listener for privacy information.
More Episodes
Every year, Fierce’s pharma, biotech, and medtech teams come together to spotlight some of the fiercest women in life sciences—leaders who are transforming the industry with their innovation and impact. This year, our special report celebrates 10 women driving change in clinical research,...
Published 11/22/24
Published 11/22/24
 Last month, the NIH announced that it had found evidence of research misconduct by Eliezer Masliah, M.D., the head of the neuroscience division at the National Institute on Aging. The NIH announcement coincided with the Sept. 26 publication of an investigation by Science, finding that 132 papers...
Published 11/15/24